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Abstract 
In this article, the use of different types of thermotherapies to treat breast cancer is reviewed. 
While hyperthermia is most commonly used as an adjuvant in combination with radiotherapy, 
chemotherapy, targeted therapy or cryotherapy to enhance the therapeutic effect of these 
therapies, thermoablation is usually carried out alone to eradicate small breast tumors. A recently 
developed thermotherapy, called magnetic hyperthermia, which involves localized heating of 
nanoparticles under the application of an alternating magnetic field, is also presented. The ad-
vantages and drawbacks of these different thermotherapies are highlighted. 
Key words: breast cancer, thermotherapies  
Introduction 
Breast cancer (BC) is a malignant tumor that 
originates from healthy mammary gland cells. The 
most common type of BC is a carcinoma originating 
from glandular tissues. BC is most frequent among 
women aged between 50 and 70, (1-3). It affects one in 
eight women on average and is the most common 
type of cancer among women, (1-3). About one mil-
lion new cases of BC are diagnosed each year world-
wide, representing about a third of new cases of all 
female cancers in industrialized countries and 15% of 
new cases in developing countries. With the im-
provement of treatments, the survival rate of women 
diagnosed with BC has increased by 2% a year during 
the last twenty years, (1-3). However, despite this 
improvement, the mortality due to BC remains sig-
nificant among women with about 20 women over 
100 000 dying from this disease each year worldwide, 
(1-3). The mortality rate of BC depends on its stage. 
While BC stages I (localized tumors of less than 2 cm) 
and II (tumors of 2 to 5 cm without nodes) can be 
cured relatively simply using surgery resulting in a 
mortality rate of less than 50%, those of grades III 
(infiltrating tumors without metastases) and IV 
(presence of metastases) are much harder to treat, 
usually require heavy treatments often involving a 
combination of surgery, chemotherapy and radio-
therapy, and result in a mortality rate of more than 
50%, (1-3).  
There are essentially three different ways to de-
crease the mortality rate of BC. Firstly, BC arises be-
cause of several risks factors, such as aging, disease 
(hyperplasia), a diet with a high intake of saturated 
fat, overweight, excessive alcohol consumption, ex-
posure to ionizing radiation, the consumption of oral 
contraceptives, hormone replacement therapy, (1-3). 
The first method, which can result in a decrease in the 
BC mortality rate, lies in the control of these risk fac-
tors, for example by making the women way of life 
healthier. Secondly, the BC mortality rate can be de-
creased by improving BC diagnosis, (1-3). The latter 
needs to be carried out frequently, accurately and 
early enough, i. e. possibly before stages III and IV of 
BC have been reached. Screening for BC can be carried 
out in three different ways. The first method involves 
self-examination of the breast. It yields controversial 
results due to the difficulty for the women to detect a 
tumor by themselves. Instead, it is usually recom-
mended that women should consult a trained doctor 
who carries out a clinical exam to detect a tumor in-
side the breast. The main and most reliable technique 
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used for BC detection is mammography. With this 
technique, an image of the inside of the breast is ob-
tained using X-rays and breast abnormalities are 
looked for. In the United States, 70% of women above 
40 years old have had a mammography during the 
last two years, (4). One of the main problems with 
mammography is the significant percentage of over-
diagnosis (∼ 10%), (5), which leads women to be di-
agnosed with BC and treated whereas their condition 
is not life threatening and in some cases will never 
cause any symptoms. The third way to decrease BC 
mortality consists in improving BC treatments. For 
that, thermotherapy can be used. This type of therapy 
is scarcely used despite its efficacy. Indeed, it has 
shown its efficacy, specifically for treatments of BC of 
stages III and IV for which the mortality rate is high 
and efficient treatments are lacking. The purpose of 
this review is to highlight the positive impacts as well 
as drawbacks of three different types of thermothera-
pies, hyperthermia, thermoablation and magnetic 
hyperthermia for BC treatment. (General information 
regarding the different types of thermotherapies is 
provided in table 1; The advantages of magnetic hy-
perthermia compared with other types of thermo-
therapies are summarized in table 2). 
Treatments commonly used to treat breast 
cancer 
The treatments commonly used to treat BC are 
first presented, (1-3). Surgery is usually divided into 
conservative surgery, which results in the removal of 
the tumor without that of the entire breast, usually 
designated as lumpectomy or partial mastectomy, 
and ‘’non conservative’’ surgery, usually designated 
as total mastectomy, which involves heavier surgery 
with the removal of the whole breast. There is a need 
to develop new techniques that can replace total 
mastectomy, which is used in 30% of all BC surgeries, 
(1-3), essentially to limit the risk of metastases, to 
preserve woman breasts. 
Radiotherapy (also called radiation therapy) is 
commonly used for patients that have either previ-
ously been treated with conservative surgery or pos-
sess metastases or lymph nodes that appear at an ad-
vanced stage of BC (typically stage III or IV), (1-3). 
Two different types of radiotherapy can be carried 
out, external radiotherapy, which uses a generator 
that directs high energy radiations (X-rays, gamma 
rays or electrons) towards the breast tumor or 
brachytherapy, in which the radiation is generated 
using a radioactive material introduced inside the 
breast. Briefly, the mechanism of tumor destruction 
by radiations involves the ionization of biological 
tissues, generating free radicals, which interact with 
biological material, cells and DNA and yield tumor 
cell death. Despite of the improvement of radiation 
therapy, for example with the development of the 
intrabeam equipment, (6), or mammosite, (7), a critical 
issue remains to be addressed: the possibility of the 
destruction of BC cells without inducing toxicity for 
healthy tissues. A therapeutic window has been iden-
tified, which corresponds to an exposure of the pa-
tient to a radiation dose of 60 to 80 Gy, (1-3). Although 
such doses result in the destruction of cancer cells 
with a relatively high probability of 40 to 100 %, they 
do not completely prevent undesirable side effects 
that can occur with a probability of 20 to 90 %, (1-3). In 
order to minimize these side effects, lower doses of 
radiation are required, which can be obtained by sen-
sitizing the tumor cells, using for example hyper-
thermia, (8).  
In chemotherapy, drugs, which are usually ad-
ministered intravenously to act on the whole body, 
are either used to prevent the development of metas-
tasis or to reduce tumor sizes. The main drawback of 
chemotherapy is due to the nonspecific targeting of 
tumor cells, which results in side effects such as hair 
losses or women overweight.  
Hormone therapy works by reducing the activity 
of female hormones, estrogen and progesterone, 
which stimulate the growth of hormone sensitive 
tumors contained in 80% of women diagnosed with 
BC, (1-3). Hormone therapies either use drugs, X-rays 
or surgery to stop the production of female hormones 
by the ovaries. As for chemotherapy, it can cause a 
number of side effects such as menopause, osteopo-
rosis or hair losses.  
Targeted therapy combined with immunother-
apy, (9), is used to treat BC that overexpresses the 
HER-2 (human epidermal growth factor receptor 2) 
gene, which promotes the growth of BC cells. Drugs 
such as Herceptin (Trastuzumab), which is an anti-
body, specifically target HER-2 and destroy the BC 
cells overexpressing HER-2 through the stimulation of 
the immune system, (10). HER-2 is however overex-
pressed only in a limited percentage of women (20 %), 
restricting the use of this therapy to only a portion of 
the women diagnosed with BC, (1-3).  
Triple negative BCs that represent ∼20% of all BC 
cases do not express HER-2 and grow without the 
support of the hormones estrogen and progesterone. 
They can’t therefore be treated with hormone therapy 
or Herceptin. 
Cryotherapy, also called cryosurgery, uses ex-
treme cold to freeze the water present in BC cells. 
Water, turned to ice crystals, along with the cold itself, 
destroys the cancer cells. It is too early to make con-
clusions regarding the efficacy of cryotherapy, since 
many of the results of studies involving this approach 
are still pending, (11). 
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Finally, two reasons for the development of new 
BC therapies such as thermotherapies can be under-
lined: 
• BC is the most important cancer among women,  
• For indications such as local regional breast 
cancer recurrence, the treatments described 
above are inefficient and BC often results in the 
death of the patient.  
 
Table 1. Summary of the physical mechanisms, procedures, preclinical and clinical data available for each type of thermotherapy de-
scribed in this review. 
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Table 2. Advantages and drawbacks of magnetic hyperthermia compared with other types of thermotherapy. 
 
 
 
BC treatments involving hyperthermia 
In hyperthermia, the temperature of the whole or 
part of the organism is raised to typical temperatures 
of 40-43 °C, (12). In this case, the antitumor activity is 
generated by heat. The latter produces (i) cytotoxic 
effects, yielding the denaturation of cytoplasmic and 
membrane tumor proteins, (ii) a decreases in blood 
flow, impairing oxygen and nutrient supply of the 
tumor and inducing tumor acidosis, (12, 13) and (iii) 
the activation of heat shock proteins, such as Hsp27, 
Hsp70 and Hsp90, which participate in the destruc-
tion of breast tumors through complex and still poorly 
understood mechanisms, (14, 15). Hyperthermia alone 
is not sufficient to treat BC. It is commonly used as an 
adjuvant and combined with other types of BC 
treatments such as chemotherapy, radiotherapy, tar-
geted therapy and cryotherapy, (16-19).  
Hyperthermia is combined with radiations to 
either treat localized recurrent BC of advanced stages 
(20, 21, 23-27) or, more rarely, primary tumors, (22). In 
this case, patients first receive a dose of radiation of 
typically 8 to 32 Gy for recurrent breast tumors that 
have previously been treated by radiotherapy (20, 21, 
24) or a dose of 60-70 Gy for superficial breast tumors 
treated for the first time, (22). It is usually not possible 
to exceed these radiation doses without causing life 
threatening conditions for the patients. It does how-
ever happen, specifically for BC of advanced stages, 
that these radiation doses are not sufficient to com-
pletely eradicate BC. In this case, hyperthermia can be 
carried out after radiations, for example by increasing 
the tumor temperature to 40-44 °C for about an hour, 
(20-23). The efficacy of a treatment combining radio-
therapy and hyperthermia was demonstrated in a 
series of clinical trials, which showed that the per-
centage of complete BC remission increases from 44%, 
(20), or 41%, (23), using radiotherapy alone to 70%, 
(20), or 59%, (23), using radiotherapy and hyperther-
mia.  
Hyperthermia can also be combined with chem-
otherapy, for example to treat metastatic breast tu-
mors. It was shown that combining whole or part 
body hyperthermia with chemotherapy increases the 
efficacy of chemotherapy, (29). A few studies also 
report the use of hyperthermia combined with both 
radiotherapy and chemotherapy for the treatment of 
recurrent localized recurrent BC, (31, 32, 33). For a 
patient with local metastases, where radiotherapy and 
chemotherapy were inefficient, the addition of hy-
perthermia at 38-41 °C led to the disappearance of the 
tumor, (31). In two other studies, this combination of 
treatments using drugs such as epirubicin and 
ifosfamide, (32), or liposomal doxorubicin, (33), led to 
20% total remission of recurrent localized BC, (33). 
Targeting therapy using HER-2 may also be combined 
with hyperthermia. For example, a system was used 
for drug delivery, which contained thermosensitive 
liposomes with HER-2 targeting molecules located at 
their surface, (30). This thermosensitive liposome de-
livered the antitumor drugs that it contained specifi-
cally at the breast tumor location after an increase of 
the tumor temperature to 39-41 °C, which enabled the 
release of the drugs specifically to the breast tumors.  
Finally, hyperthermia was also used in combi-
nation with cryotherapy. The efficacy of this com-
bined treatment was shown for the treatment of a 
large metastatic breast tumor of 12 cm in diameter, 
which could not successfully be treated by cryosur-
gery alone but disappeared completely when cryo-
surgery was combined with hyperthermia, (34).  
Hyperthermia was generated in several different 
ways using a microwave applicator operating at 433 
MHz (18, 21, 24), a Sigma 60 applicator for part body 
hyperthermia, (26), or a radiant system for whole 
body hyperthermia, (28). With a radiant system, a 
temperature of 42 °C can be maintained throughout 
the whole body during an hour. Other hyperthermia 
systems include the Aquatherm and Iratherm systems 
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in which heating is induced by far-infrared radiations, 
which heat the blood under the skin and gradually 
heat the whole body in 60-90 minutes.  
Treatments of breast cancer by thermo-
ablation 
In thermal ablation, the tumor temperature is 
raised above 43 °C, resulting in larger cytotoxic effects 
than in hyperthermia and in the direct destruction of 
the breast tumor. Since thermal ablation alone is usu-
ally sufficient to destroy breast tumor tissues, it is 
often not combined with other types of BC treatments. 
Thermoablation enables to treat localized breast tu-
mors of small sizes (2 to 6 cm), (35-37, 39-47) and more 
rarely metastatic liver tumors originating from BC, 
(38). During the treatment, the tumor temperature is 
typically raised to 90-95 °C during 10 to 15 minutes 
using radiofrequencies, (35,37), or to 46-50 °during 60 
seconds using microwaves, (38), to 60-90 °C during 
one to two hours using high intensity focused ultra-
sound (HIFU), (44, 45), or to 48 °C during 30 minutes 
using interstitial laser thermotherapy (ILT or LITT), 
(48). The heat can be produced by different types of 
equipment, such as an RF 460 monopolar electrosur-
gical generator from RITA Medical system, (35, 37), a 
JC200 from Chongqing Haifu Technology, (42, 43), a 
microwave coagulator operating at 2.45 GHz, (38), or 
a Yag: ND pulsed laser, (48), for radiofrequency, 
HIFU, microwave and LITT thermotherapies, respec-
tively. Magnetic resonance temperature imaging 
(MRTI), ultrasound or ultrasonography can be used to 
measure the tumor temperature during the treatment 
and to try to prevent overheating of healthy tissues, 
(44). MRTI provides an estimate of the temperature by 
measuring the molecular diffusion coefficient, the 
longitudinal relaxation time T1 or the proton reso-
nance frequency of tissue water, which depends on 
water, (49). Ultrasounds and ultrasonography meas-
ure the echo shifts due to changes in tissue thermal 
expansion and speed of sound, the variation in the 
attenuation coefficient or the change in backscattered 
energy from tissue inhomogeneity, (50). These treat-
ments have shown efficacy. For example, using mi-
crowaves, it was possible to destroy 100 % of breast 
tumors, (38). Clinical trials on BC involving HIFU also 
led to the complete (or almost complete) disappear-
ance of breast tumors, (42). However, these thermo-
therapies possess a drawback, which comes from the 
high temperatures, which are needed to achieve high 
efficacy. Without a method to predict and measure 
accurately these temperatures, the latter can result in 
side effects, including the destruction of healthy tis-
sues.  
 
Figure 1. Schematic diagrams showing the different steps of a typical 
treatment involving magnetic hyperthermia. 
 
Magnetic hyperthermia 
In magnetic hyperthermia, nanoparticles are 
administrated (or sent) to tumors and heated under 
the application of an alternating magnetic field. The 
heat produced by the nanoparticles induces an-
ti-tumor activity. The advantages of magnetic hyper-
thermia compared with the other heating techniques 
described above come from: (i), the cellular internali-
zation of the nanoparticles under the application of an 
alternating magnetic field, which yields more efficient 
tumor destruction than extracellular heating usually 
achieved with the other heating methods, (57-60), (ii), 
the possibility to target the tumors, for example by 
attaching to the nanoparticles molecules that specifi-
cally recognize the cancer cells and, (iii), the fine 
temperature tuning that can be achieved by accurately 
selecting the strength or intensity of the applied al-
ternating magnetic field and the quantity of nanopar-
ticles administered, (iv), the very localized heat that 
shall prevent damaging healthy tissues surrounding 
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the tumor. Two different types of nanoparticles have 
been tested for magnetic hyperthermia treatment of 
BC, chemically synthesized nanoparticles, which are 
the most frequently studied, and biologically pro-
duced nanoparticles, synthesized by magnetotactic 
bacteria, called magnetosomes. 
Usually, chemically synthesized nanoparticles 
used to carry out magnetic hyperthermia on BC are 
small, typically less than 20 nm, made of maghemite 
or magnetite and superparamagnetic, which means 
that they possess a thermally unstable magnetic mo-
ment, (51-56). Magnetic hyperthermia has success-
fully been tested on breast tumors xeno-grafted under 
the skin of mice. For that, 1 to 2 mg of nanoparticles, 
(51-53), have been administered either intravenously, 
(51, 52), or directly to tumors, (53), of typical sizes 100 
to 200 mm3, (51, 52). Specific targeting of the tumors 
was achieved by using 111InCh antibody, (51, 52), or 
anti-HER2 molecules attached either to the nanopar-
ticles, (53-55), or to the liposomes containing the na-
noparticles, (56). In order to generate heat, the nano-
particles were exposed to an alternating magnetic 
field of strength 12-130 mT and frequency of 118-360 
kHz during 20-30 minutes, (51-56). The efficacy of 
these preclinical treatments was revealed by the dis-
appearance of the tumors, (51-56). Clinical trials using 
magnetic hyperthermia are ongoing at the University 
of Nagoya to treat BC. Figure 1 shows the different 
steps, which may be involved in the treatment of BC 
using magnetic hyperthermia. Breast tumor may first 
be diagnosed using mammography. The nanoparticle 
suspension may then be administered to the breast 
tumor using a syringe. MRI may be used to visualize 
the nanoparticles during and after the administration 
of the nanoparticle suspension and to verify the cor-
rect location of the nanoparticles in the tumor before 
and during the treatment. After that, the patient may 
be positioned inside an instrument that generates an 
alternating magnetic field and heats the nanoparticles 
contained in the tumor. After treatment, the variation 
of the tumor size may be followed by MRI. 
In order to increase the amount of heat deliv-
ered, nanoparticles synthesized by magnetotactic 
bacteria, called magnetosomes, which are usually 
larger, with average sizes lying between 40 and 60 
nm, better crystallized and which possess a more sta-
ble magnetic moment than chemically synthesized 
nanoparticles, (57-65), have been tested preclinically 
for BC treatment, (57-60). Figure 2 illustrates the ex-
perimental protocol, which was used during the 
treatment of the mice. Shortly, 100 µl of a suspension 
containing 1 mg of chains of magnetosomes, extracted 
from magnetotactic bacteria and mixed in water, was 
administered to MDA-MB-231 breast tumors 
xeno-grafted under the skin of mice. The mice were 
then exposed three times during twenty minutes to an 
alternating magnetic field of average field strength 20 
mT and frequency 198 kHz. The treatment led to the 
complete disappearance 
of the tumor in several 
mice 30 days after the 
treatment as shown in 
Figure 2, (57).  
 
 
 
Figure 2. A series of Figures 
showing the different steps of a 
treatment of MDA-MB-231 breast 
tumors xeno-grafted under the 
skin of a mouse using magnetic 
hyperthermia. The nanoparticle 
suspensions are first administered 
to the tumors, (a). The mouse is 
then positioned inside a coil that 
generates an alternating magnetic 
field of average field strength 20 
mT and frequency 198 kHz to heat 
the nanoparticle contained in the 
tumors, (b). The treatment results 
in the disappearance of the tumor 
using the magnetosomes, (c), while 
it does not destroy the tumor 
using chemically synthesized na-
noparticles, (d). 
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For the mice, which were treated in the same 
way, but with a suspension containing 1 mg of chem-
ically synthesized nanoparticles instead of the mag-
netosome, the treatment was inefficient and the tumor 
was still there 30 days following the beginning of the 
treatment as shown in Figure 2. It was therefore 
demonstrated that the magnetic hyperthermia treat-
ment of BC was more efficient using magnetosomes 
than two types of chemically synthesized nanoparti-
cles (SPION covered with PEG or citrate molecules) 
both in vivo on MDA-MB231 tumors and in vitro on 
MDA-MB231 cells and hella cells, (57) .  
The physical mechanisms, procedures, 
pre-preclinical and clinical data, available on each of 
the different types of thermotherapy are summarized 
in table 1.  
Conclusion 
In conclusion, two types of thermotherapies, 
hyperthermia that is usually combined with other 
commonly used BC treatments, and thermoablation, 
which is often used alone, have been described. The 
results obtained with an emerging thermotherapy, 
called magnetic hyperthermia, in which magnetic 
nanoparticles are heated inside tumors under the ap-
plication of an alternating magnetic field, have also 
been presented. The advantages and drawbacks of 
magnetic hyperthermia compared with the other 
thermotherapies are summarized in table 2. In prac-
tice, hyperthermia may essentially be used for the 
treatment of recurrent localized breast tumor of stages 
III and IV, while thermoablation may be carried out 
on small localized tumors. Since hyperthermia and 
thermoablation have both shown efficacy, there is no 
reason why they should not be used more frequently 
for the treatment of these indications. Magnetic hy-
perthermia is a promising thermotherapy, but re-
search still needs to be carried out on several aspects 
such as the specific targeting of the tumor by the na-
noparticles, the control of the heat released by the 
nanoparticles and the nanoparticle toxicity in order to 
be able to use it routinely for BC treatment.  
The cost of breast cancer is about 30 billion $ a 
year, with 30% and 50% of this cost being attributed to 
productivity loss and medical costs respectively. The 
loss in productivity and medical costs can be mini-
mized by developing new, improved and less expen-
sive treatments, such as those described in this re-
view.  
Methods used for the literature search 
Pubmed, medline, google, google scholar and 
clinicaltrials.gov were used for the literature search 
with keywords such as: thermotherapy, hyperther-
mia, thermoablation, magnetic hyperthermia, breast 
cancer, breast tumor. 
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